Post-COVID-19 pulmonary fibrosis: An ongoing concern

Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae includi...

Full description

Saved in:
Bibliographic Details
Published in:Annals of thoracic medicine 2023-10, Vol.18 (4), p.173-181
Main Author: Alrajhi, Nuha
Format: Article
Language:English
Subjects:
Coronaviruses
COVID-19
Development and progression
Immunosuppressive agents
Physiological aspects
Pulmonary fibrosis
Review
Risk factors
Severe acute respiratory syndrome
severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c748r-7fa361f26cf89eaacee35b893d00d86796152afaf12703984c2940c659dea74d3
cites cdi_FETCH-LOGICAL-c748r-7fa361f26cf89eaacee35b893d00d86796152afaf12703984c2940c659dea74d3
container_end_page 181
container_issue 4
container_start_page 173
container_title Annals of thoracic medicine
container_volume 18
creator Alrajhi, Nuha
description Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae including pulmonary, neurological, psychological, and cardiovascular complications. Post-COVID-19 pulmonary fibrosis is one of the major concerns arising after the recovery from this pandemic. Risk factors for post-COVID-19 pulmonary fibrosis include age, male sex, and the severity of COVID-19 disease. High-resolution computed tomography provides diagnostic utility to diagnose pulmonary fibrosis as it provides more details regarding the pattern and the extent of pulmonary fibrosis. Emerging data showing similarities between post-COVID-19 pulmonary fibrosis and idiopathic pulmonary fibrosis, finding that needs further exploration. The management of post-COVID-19 pulmonary fibrosis depends on many factors but largely relies on excluding other causes of pulmonary fibrosis, the extent of fibrosis, and physiological impairment. Treatment includes immunosuppressants versus antifibrotics or both.
doi_str_mv 10.4103/atm.atm_7_23
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_53cb3973ff1744f4b0cfa059a752949a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A818911498</galeid><doaj_id>oai_doaj_org_article_53cb3973ff1744f4b0cfa059a752949a</doaj_id><sourcerecordid>A818911498</sourcerecordid><originalsourceid>FETCH-LOGICAL-c748r-7fa361f26cf89eaacee35b893d00d86796152afaf12703984c2940c659dea74d3</originalsourceid><addsrcrecordid>eNqdk0uP0zAURiMEYobCjjWqxIYFKXauHdtsUFVelSoNC2BruY4d3EnsYidU_HtcOh21aDQLFEWxnOOT6_i7RfEcoxnBCN6ooZ_lWzJZwYPiEgvBS6CUPcxjjlmJGbCL4klKG4RoTYA9Li6AI8qZQJcF-RLSUC6uvi_fl1hMt2PXB6_i76l16xiSS2-ncz8Nvg3Ot1MdvDbRPy0eWdUl8-zmOSm-ffzwdfG5XF19Wi7mq1IzwmPJrIIa26rWlgujlDYG6JoLaBBqeM1EjWmlrLK4YggEJ7oSBOmaisYoRhqYFMuDtwlqI7fR9bkyGZSTfydCbKWKg9OdkRT0GgQDazEjxJI10lYhKhSjWSpUdr07uLbjujeNNn6IqjuTnr_x7odswy-JUZ29iGTDqxtDDD9HkwbZu6RN1ylvwphkxYUABlhUGX35D7oJY_T5X0nABBEqKgz3URXndQXA4YRqVd6n8zbk8vT-03LOMRcYE8HvpRjDdY5Krm5SlHdQrfEm7zh4Y12ePrPO7uDz1Zje6f9fcFrR68MCndOWorG3J4KR3Odb7rN9zHfGX5ye4i18DHQGVgdgF7rBxHTdjTsTZWavfdjdKZW5Q-RZG8hjG8Afe5gLtQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2886233833</pqid></control><display><type>article</type><title>Post-COVID-19 pulmonary fibrosis: An ongoing concern</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Alrajhi, Nuha</creator><creatorcontrib>Alrajhi, Nuha</creatorcontrib><description>Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae including pulmonary, neurological, psychological, and cardiovascular complications. Post-COVID-19 pulmonary fibrosis is one of the major concerns arising after the recovery from this pandemic. Risk factors for post-COVID-19 pulmonary fibrosis include age, male sex, and the severity of COVID-19 disease. High-resolution computed tomography provides diagnostic utility to diagnose pulmonary fibrosis as it provides more details regarding the pattern and the extent of pulmonary fibrosis. Emerging data showing similarities between post-COVID-19 pulmonary fibrosis and idiopathic pulmonary fibrosis, finding that needs further exploration. The management of post-COVID-19 pulmonary fibrosis depends on many factors but largely relies on excluding other causes of pulmonary fibrosis, the extent of fibrosis, and physiological impairment. Treatment includes immunosuppressants versus antifibrotics or both.</description><identifier>ISSN: 1817-1737</identifier><identifier>EISSN: 1998-3557</identifier><identifier>DOI: 10.4103/atm.atm_7_23</identifier><identifier>PMID: 38058790</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Coronaviruses ; COVID-19 ; Development and progression ; Immunosuppressive agents ; Physiological aspects ; Pulmonary fibrosis ; Review ; Risk factors ; Severe acute respiratory syndrome ; severe acute respiratory syndrome coronavirus 2</subject><ispartof>Annals of thoracic medicine, 2023-10, Vol.18 (4), p.173-181</ispartof><rights>Copyright: © 2023 Annals of Thoracic Medicine.</rights><rights>COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd.</rights><rights>2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2023 Annals of Thoracic Medicine 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c748r-7fa361f26cf89eaacee35b893d00d86796152afaf12703984c2940c659dea74d3</citedby><cites>FETCH-LOGICAL-c748r-7fa361f26cf89eaacee35b893d00d86796152afaf12703984c2940c659dea74d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697304/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2886233833?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,25736,27907,27908,36995,36996,44573,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38058790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alrajhi, Nuha</creatorcontrib><title>Post-COVID-19 pulmonary fibrosis: An ongoing concern</title><title>Annals of thoracic medicine</title><addtitle>Ann Thorac Med</addtitle><description>Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae including pulmonary, neurological, psychological, and cardiovascular complications. Post-COVID-19 pulmonary fibrosis is one of the major concerns arising after the recovery from this pandemic. Risk factors for post-COVID-19 pulmonary fibrosis include age, male sex, and the severity of COVID-19 disease. High-resolution computed tomography provides diagnostic utility to diagnose pulmonary fibrosis as it provides more details regarding the pattern and the extent of pulmonary fibrosis. Emerging data showing similarities between post-COVID-19 pulmonary fibrosis and idiopathic pulmonary fibrosis, finding that needs further exploration. The management of post-COVID-19 pulmonary fibrosis depends on many factors but largely relies on excluding other causes of pulmonary fibrosis, the extent of fibrosis, and physiological impairment. Treatment includes immunosuppressants versus antifibrotics or both.</description><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Development and progression</subject><subject>Immunosuppressive agents</subject><subject>Physiological aspects</subject><subject>Pulmonary fibrosis</subject><subject>Review</subject><subject>Risk factors</subject><subject>Severe acute respiratory syndrome</subject><subject>severe acute respiratory syndrome coronavirus 2</subject><issn>1817-1737</issn><issn>1998-3557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqdk0uP0zAURiMEYobCjjWqxIYFKXauHdtsUFVelSoNC2BruY4d3EnsYidU_HtcOh21aDQLFEWxnOOT6_i7RfEcoxnBCN6ooZ_lWzJZwYPiEgvBS6CUPcxjjlmJGbCL4klKG4RoTYA9Li6AI8qZQJcF-RLSUC6uvi_fl1hMt2PXB6_i76l16xiSS2-ncz8Nvg3Ot1MdvDbRPy0eWdUl8-zmOSm-ffzwdfG5XF19Wi7mq1IzwmPJrIIa26rWlgujlDYG6JoLaBBqeM1EjWmlrLK4YggEJ7oSBOmaisYoRhqYFMuDtwlqI7fR9bkyGZSTfydCbKWKg9OdkRT0GgQDazEjxJI10lYhKhSjWSpUdr07uLbjujeNNn6IqjuTnr_x7odswy-JUZ29iGTDqxtDDD9HkwbZu6RN1ylvwphkxYUABlhUGX35D7oJY_T5X0nABBEqKgz3URXndQXA4YRqVd6n8zbk8vT-03LOMRcYE8HvpRjDdY5Krm5SlHdQrfEm7zh4Y12ePrPO7uDz1Zje6f9fcFrR68MCndOWorG3J4KR3Odb7rN9zHfGX5ye4i18DHQGVgdgF7rBxHTdjTsTZWavfdjdKZW5Q-RZG8hjG8Afe5gLtQ</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Alrajhi, Nuha</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><general>Wolters Kluwer - Medknow</general><general>Wolters Kluwer Medknow Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20231001</creationdate><title>Post-COVID-19 pulmonary fibrosis: An ongoing concern</title><author>Alrajhi, Nuha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c748r-7fa361f26cf89eaacee35b893d00d86796152afaf12703984c2940c659dea74d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Development and progression</topic><topic>Immunosuppressive agents</topic><topic>Physiological aspects</topic><topic>Pulmonary fibrosis</topic><topic>Review</topic><topic>Risk factors</topic><topic>Severe acute respiratory syndrome</topic><topic>severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alrajhi, Nuha</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Annals of thoracic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alrajhi, Nuha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Post-COVID-19 pulmonary fibrosis: An ongoing concern</atitle><jtitle>Annals of thoracic medicine</jtitle><addtitle>Ann Thorac Med</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>18</volume><issue>4</issue><spage>173</spage><epage>181</epage><pages>173-181</pages><issn>1817-1737</issn><eissn>1998-3557</eissn><abstract>Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae including pulmonary, neurological, psychological, and cardiovascular complications. Post-COVID-19 pulmonary fibrosis is one of the major concerns arising after the recovery from this pandemic. Risk factors for post-COVID-19 pulmonary fibrosis include age, male sex, and the severity of COVID-19 disease. High-resolution computed tomography provides diagnostic utility to diagnose pulmonary fibrosis as it provides more details regarding the pattern and the extent of pulmonary fibrosis. Emerging data showing similarities between post-COVID-19 pulmonary fibrosis and idiopathic pulmonary fibrosis, finding that needs further exploration. The management of post-COVID-19 pulmonary fibrosis depends on many factors but largely relies on excluding other causes of pulmonary fibrosis, the extent of fibrosis, and physiological impairment. Treatment includes immunosuppressants versus antifibrotics or both.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>38058790</pmid><doi>10.4103/atm.atm_7_23</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1817-1737
ispartof Annals of thoracic medicine, 2023-10, Vol.18 (4), p.173-181
issn 1817-1737
1998-3557
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_53cb3973ff1744f4b0cfa059a752949a
source Publicly Available Content Database; PubMed Central
subjects Coronaviruses
COVID-19
Development and progression
Immunosuppressive agents
Physiological aspects
Pulmonary fibrosis
Review
Risk factors
Severe acute respiratory syndrome
severe acute respiratory syndrome coronavirus 2
title Post-COVID-19 pulmonary fibrosis: An ongoing concern
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A45%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Post-COVID-19%20pulmonary%20fibrosis:%20An%20ongoing%20concern&rft.jtitle=Annals%20of%20thoracic%20medicine&rft.au=Alrajhi,%20Nuha&rft.date=2023-10-01&rft.volume=18&rft.issue=4&rft.spage=173&rft.epage=181&rft.pages=173-181&rft.issn=1817-1737&rft.eissn=1998-3557&rft_id=info:doi/10.4103/atm.atm_7_23&rft_dat=%3Cgale_doaj_%3EA818911498%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c748r-7fa361f26cf89eaacee35b893d00d86796152afaf12703984c2940c659dea74d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2886233833&rft_id=info:pmid/38058790&rft_galeid=A818911498&rfr_iscdi=true